Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Company profile
Ticker
COEPW, COEP
Exchange
Website
CEO
Mr. David Mehalick
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Bull Horn Holdings Corp.
SEC CIK
Corporate docs
Subsidiaries
Coeptis Therapeutics, Inc. • Coeptis Pharmaceuticals, Inc. • Coeptis Pharmaceuticals LLC ...
COEPW stock data
Latest filings (excl ownership)
8-K
Coeptis Therapeutics Granted Continued Listing from Nasdaq Hearings Panel to Regain Compliance with Nasdaq Listing Requirements
19 Sep 24
424B3
Prospectus supplement
16 Aug 24
424B3
Prospectus supplement
16 Aug 24
10-Q
2024 Q2
Quarterly report
15 Aug 24
10-K/A
2023 FY
Annual report (amended)
15 Aug 24
NT 10-Q
Notice of late quarterly filing
14 Aug 24
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
14 Aug 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
31 Jul 24
Latest ownership filings
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.56 mm | 1.56 mm | 1.56 mm | 1.56 mm | 1.56 mm | 1.56 mm |
Cash burn (monthly) | (no burn) | 140.81 k | 1.01 mm | 1.48 mm | 472.58 k | 581.02 k |
Cash used (since last report) | n/a | 409.02 k | 2.94 mm | 4.29 mm | 1.37 mm | 1.69 mm |
Cash remaining | n/a | 1.15 mm | -1.38 mm | -2.73 mm | 182.35 k | -132.66 k |
Runway (months of cash) | n/a | 8.1 | -1.4 | -1.9 | 0.4 | -0.2 |
Institutional ownership, Q2 2024
28.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 36 |
Opened positions | 31 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 500.22 mm |
Total shares | 11.49 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bull Horn Holdings Sponsor | 4.88 mm | $0.00 |
Meteora Capital | 1.64 mm | $155.96 mm |
Lena Pharma | 1.43 mm | $0.00 |
Lisa Pharma | 1.43 mm | $0.00 |
Creative Planning | 645.10 k | $186.44 mm |
Geode Capital Management | 198.85 k | $57.48 mm |
Rivernorth Capital Management | 150.00 k | $4.50 mm |
HRT Financial | 113.12 k | $5.00 k |
Walleye Capital | 109.05 k | $3.27 mm |
Cantor Fitzgerald, L. P. | 106.46 k | $12.78 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Jan 24 | Tara DeSilva | Common Stock | Buy | Acquire P | No | No | 0.58 | 1,800 | 1.04 k | 32,266 |
12 Jan 24 | Tara DeSilva | Common Stock | Buy | Acquire P | No | No | 0.56 | 466 | 260.96 | 30,466 |
10 Jan 24 | Brian Cogley | Common Stock | Buy | Acquire P | No | No | 0 | 5,000 | 0.00 | 30,000 |
8 Jan 24 | David Mehalick | Common Stock | Buy | Acquire P | No | No | 0.66 | 14,004 | 9.24 k | 2,782,615 |
8 Jan 24 | David Mehalick | Common Stock | Buy | Acquire P | No | No | 0.67 | 6,000 | 4.02 k | 2,768,611 |
5 Jan 24 | Christopher P. Cochran | Common Stock | Buy | Acquire P | No | No | 0 | 7,000 | 0.00 | 37,000 |
5 Jan 24 | David Mehalick | Common Stock | Buy | Acquire P | No | No | 0.69 | 5,050 | 3.48 k | 2,762,611 |